CDKN2A and non-small cell lung carcinoma: p16 hypermethylation was significantly associated with OS of patients with NSCLC in Asia (HR 1.65, 1.16–2.35) and USA (HR 1.89, 1.27–2.82), and with OS of patients with CRC in Asia (HR 3.30, 1.68–6.46) and Europe (HR 1.49, 1.05–2.09) (Table 1).